Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

US FDA approves GSK's second lung cancer drug from historic Nuvalent deal | Reuters

ReutersView source article

Part of story

GSK wins FDA approval for neladalkib lung cancer drug from Nuvalent deal

The FDA granted accelerated approval to GSK's oral lung cancer drug neladalkib (Nelkarmi) for patients with advanced RET-altered non-small cell lung cancer, the second regulatory win from its $10.6 billion Nuvalent acquisition.

Nov 17, 2026·4 sourcesPharmaceutical IndustryCancer treatmentFDA drug approvalCancer and Cancer TreatmentAccelerated approval pathwaysDrug Policy, Pricing & ApprovalMergers & acquisitions (M&A)Cancer & OncologyMergers and acquisitionsTargeted cancer therapy
GSK wins FDA approval for neladalkib lung cancer drug from Nuvalent deal
00

Other sources for this story

Bloomberg

GSK Wins US Approval for Nelkarmi Lung Cancer Drug After Nuvalent Acquisition

Financial Times

GSK wins approval for second lung cancer drug from $10.6bn Nuvalent deal

Endpoints

GSK’s Nuvalent buyout delivers again as FDA clears Nelkarmi for lung cancer